Confrontation Phenotypes and Genotypes of Epithelial Odontogenic Tumors of the Jaws
NCT02167581 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 319
Last updated 2015-04-24
Summary
Systematically compare the phenotype and genotype of epithelial odontogenic tumors in children and adults with a clinical, radiographic, pathologic and molecular level.
Either:
establish an observatory of this multidisciplinary tumor establish a tumor bank annotated scale unparalleled testing pathophysiological hypotheses search for prognostic factors.
Conditions
- Epithelial Odontogenic Tumours
Sponsors & Collaborators
-
Assistance Publique - Hôpitaux de Paris
lead OTHER
Principal Investigators
-
Blandine Ruhin, MD, PhD · Assistance Publique - Hôpitaux de Paris
Eligibility
- Min Age
- 5 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2011-01-31
- Primary Completion
- 2014-09-30
- Completion
- 2014-09-30
Countries
- France
Study Locations
More Related Trials
-
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma
NCT07072351 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Molecular Analysis of Gastric and OEsophageal Cancers STudy
NCT06702384 ·Status: WITHDRAWN
-
Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC
NCT05507411 ·Status: RECRUITING ·Phase: PHASE2
-
Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT06888531 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
NCT06190782 ·Status: RECRUITING ·Phase: PHASE3
-
Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma
NCT02731313 ·Status: COMPLETED
-
Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
NCT07317609 ·Status: RECRUITING ·Phase: PHASE1
-
Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Esophagogastric Junction Adenocarcinoma
NCT05505461 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.
NCT06020885 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients
NCT05252078 ·Status: RECRUITING ·Phase: PHASE2
-
Safety Study of Multiple Peptide Vaccine to Esophageal Cancer
NCT00561275 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
NCT05319730 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer
NCT05050760 ·Status: UNKNOWN ·Phase: NA
-
Multi-omics Monitoring of Dynamic Evolution in Esophageal Squamous Cell Carcinoma: PKU-ESCC-Monitor
NCT07152535 ·Status: NOT_YET_RECRUITING
-
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
NCT00561197 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
NCT05552651 ·Status: UNKNOWN ·Phase: PHASE2
-
Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma
NCT07182565 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
NCT04973306 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma
NCT06912074 ·Status: RECRUITING ·Phase: PHASE2
-
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
NCT06173986 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma
NCT02916511 ·Status: COMPLETED ·Phase: PHASE2
-
RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus
NCT00559351 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy Evaluation and Recurrence Monitoring of Therapy for Esophageal Squamous Cell Carcinoma Based on ctDNA-MRD.
NCT05900583 ·Status: UNKNOWN
-
Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction
NCT02287129 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
NCT04974047 ·Status: COMPLETED ·Phase: PHASE2